

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
7 December 2000 (07.12.2000)

PCT

(10) International Publication Number
WO 00/72799 A2


- (51) International Patent Classification⁷: A61K (74) Agent: VIKSNINS, Ann, S.; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US).
- (21) International Application Number: PCT/US00/14548
- (22) International Filing Date: 26 May 2000 (26.05.2000) (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/320,769 27 May 1999 (27.05.1999) US
- (71) Applicant (for all designated States except US): THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION [US/US]; Suite 1-110, 1224 West Main Street, Charlottesville, VA 22903 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): LINDEN, Joel, M. [US/US]; 207 Harvest Drive, Charlottesville, VA 22903 (US). SULLIVAN, Gail, W. [US/US]; 568 Taylor's Gap Road, Charlottesville, VA 22903 (US). SAREMBOCK, Ian, J. [US/US]; Box 158, Charlottesville, VA 22903 (US). SCHELD, W., Michael [US/US]; 2075 Earlysville Road, Earlysville, VA 22936 (US).
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD AND COMPOSITIONS FOR TREATING THE INFLAMMATORY RESPONSE

(57) Abstract: Agonists of A_{2A} adenosine receptors optionally, in combination with a Type IV phosphodiesterase (PDE) inhibitor are effective for the treatment of the inflammatory response of mammalian tissue.

WO 00/72799 A2

METHOD AND COMPOSITIONS FOR TREATING THE INFLAMMATORY RESPONSE

5

The present invention was made with the assistance of U.S. Government funding (NIH Grant R01-HL 37942). The U.S. Government may have certain rights in this invention.

Related Application

- 10 This application is a continuation-in-part of co-pending United States patent application Serial No. 09/003930, which in turn is a continuation-in-part of Serial No. 08/272,821, filed July 22, 1994 to Linden et al. (U.S. Patent No. 5,877,180), which are incorporated herein in its entirety by reference.

Background of the Invention

15 Field of the invention

The present invention relates to methods and compositions for treating the inflammatory response in mammalian tissue.

Discussion of the Background

- 20 The release of inflammatory cytokines such as tumor necrosis factor-alpha (TNF α) by leukocytes is a means by which the immune system combats pathogenic invasions, including infections. Cytokines stimulate neutrophils to enhance oxidative (e.g., superoxide and secondary products) and nonoxidative (e.g., myeloperoxidase and other enzymes) inflammatory activity. Inappropriate and over-release of cytokines can produce counterproductive exaggerated
- 25 pathogenic effects through the release of tissue-damaging oxidative and nonoxidative products (Tracey, K. G. et al., J. Exp. Med., 167, 1211-1227 (1988); and Männel, D. N. et al., Rev. Infect. Dis., 9 (suppl 5), S602-S606 (1987)).

- For example, inflammatory cytokines have been shown to be pathogenic
- 30 in: arthritis (Dinareello, C. A., Semin. Immunol., 4, 133-45 (1992)); ischemia (Seekamp, A. et al., Agents-Actions-Supp., 41, 137-52 (1993)); septic shock (Männel, D. N. et al., Rev. Infect. Dis., 9 (suppl 5), S602-S606 (1987)); asthma (Cembrzynska Nowak M. et al., Am. Rev. Respir. Dis., 147, 291-5 (1993)); organ transplant rejection (Imagawa, D. K. et al., Transplantation, 51, 57-62

(1991)); multiple sclerosis (Hartung, H. P., Ann. Neurol., **33**, 591-6 (1993)); and AIDS (Matsuyama, T. et al., AIDS, **5**, 1405-1417 (1991)). In addition, superoxide formation in leukocytes has been implicated in promoting replication of the human immunodeficiency virus (HIV) (Legrand-Poels, S. et al., AIDS Res. Hum. Retroviruses, **6**, 1389-1397 (1990)).

It is well known that adenosine and some adenosine analogs that nonselectively activate adenosine receptor subtypes decrease neutrophil production of inflammatory oxidative products (Cronstein, B. N. et al., Ann. N.Y. Acad. Sci., **451**, 291-314 (1985); Roberts, P. A. et al., Biochem. J., **227**, 669-674 (1985); Schrier, D. J. et al., J. Immunol., **137**, 3284-3289 (1986); Cronstein, B. N. et al., Clinical Immunol. and Immunopath., **42**, 76-85 (1987); Iannone, M. A. et al., in Topics and Perspectives in Adenosine Research, E. Gerlach et al., eds., Springer-Verlag, Berlin, 286-298 (1987); McGarrity, S. T. et al., J. Leukocyte Biol., **44**, 411-421 (1988); De La Harpe, J. et al., J. Immunol., **143**, 596-602 (1989); McGarrity, S. T. et al., J. Immunol., **142**, 1986-1994 (1989); and Nielson, C. P. et al., Br. J. Pharmacol., **97**, 882-888 (1989)). For example, adenosine has been shown to inhibit superoxide release from neutrophils stimulated by chemoattractants such as the synthetic mimic of bacterial peptides, f-met-leu-phe (fMLP), and the complement component C_{3a} (Cronstein, B. N. et al., J. Immunol., **135**, 1366-1371 (1985)). Adenosine can decrease the greatly enhanced oxidative burst of PMNs (neutrophils) first primed with TNF α (an inflammatory cytokine) and then exposed to a second stimulus such as f-met-leu-phe (Sullivan, G. W. et al., Clin. Res., **41**, 172A (1993)). There is evidence that *in vivo* adenosine has anti-inflammatory activity (Firestein, G. S. et al., Clin. Res., **41**, 170A (1993); and Cronstein, B. N. et al., Clin. Res., **41**, 244A (1993)). Additionally, it has been reported that adenosine can decrease the rate of HIV replication in a T-cell line (Sipka, S. et al., Acta. Biochim. Biophys. Hung., **23**, 75-82 (1988)).

It has been suggested that there is more than one subtype of adenosine receptor on neutrophils that have opposite effects on superoxide release (Cronstein, B. N. et al., J. Clin. Invest., **85**, 1150-1157 (1990)). The existence of the A_{2a} receptor on neutrophils was originally demonstrated by Van Calker et al. (Van Calker, D. et al., Eur. J. Pharmacology, **206**, 285-290 (1991)).


(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
7 December 2000 (07.12.2000)

PCT

(10) International Publication Number
WO 00/72799 A3

- (51) International Patent Classification: A61K 31/00, 31/7076, A61P 29/00 // (A61K 31/7076, 31:4015)
- (21) International Application Number: PCT/US00/14548
- (22) International Filing Date: 26 May 2000 (26.05.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/320,769 27 May 1999 (27.05.1999) US
- (71) Applicant (for all designated States except US): THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION [US/US]; Suite 1-110, 1224 West Main Street, Charlottesville, VA 22903 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): LINDEN, Joel, M. [US/US]; 207 Harvest Drive, Charlottesville, VA 22903 (US). SULLIVAN, Gail, W. [US/US]; 568 Taylor's Gap Road, Charlottesville, VA 22903 (US). SAREMBOCK, Ian, J. [US/US]; Box 158, Charlottesville, VA 22903 (US). SCHELD, W., Michael [US/US]; 2075 Earlysville Road, Earlysville, VA 22936 (US).
- (74) Agent: VIKSNINS, Ann, S.; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— With international search report.
- (88) Date of publication of the international search report: 12 July 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD AND COMPOSITIONS FOR TREATING THE INFLAMMATORY RESPONSE


(57) Abstract: Agonists of A_{2A} adenosine receptors optionally, in combination with a Type IV phosphodiesterase (PDE) inhibitor are effective for the treatment of the inflammatory response of mammalian tissue.

WO 00/72799 A3

There has been progressive development of compounds that are more and more potent and selective as agonists of A_{2A} adenosine receptors based on radioligand binding assays and physiological responses. Initially, compounds with little or no selectivity for A_{2A} receptors were used, such as adenosine itself or 5'-carboxamides of adenosine, such as 5'-N-ethylcarboxamidoadenosine (NECA) (Cronstein, B. N. et al., J. Immunol., **135**, 1366-1371 (1985)). Later it was shown that addition of 2-alkylamino substituents increased potency and selectivity, e.g., CV1808 and CGS21680 (Jarvis, M. F. et al., J. Pharmacol. Exp. Ther., **251**, 888-893 (1989)). 2-Alkoxy-substituted adenosine derivatives such as WRC-0090 are even more potent and selective as agonists on the coronary artery A_{2A} receptor (Ukena, M. et al., J. Med. Chem., **34**, 1334-1339 (1991)). The 2-alkylhydrazino adenosine derivatives, e.g., SHA 211 (also called WRC-0474) have also been evaluated as agonists at the coronary artery A_{2A} receptor (Niiya, K. et al., J. Med. Chem., **35**, 4557-4561 (1992)).

There is one report of the combination of relatively nonspecific adenosine analogs, R-phenylisopropyladenosine (R-PIA) and 2-chloroadenosine (Cl-Ado) with a phosphodiesterase (PDE) inhibitor resulting in a lowering of neutrophil oxidative activity (Iannone, M. A. et al., in Topics and Perspectives in Adenosine Research, E. Gerlach et al., Eds., Springer-Verlag, Berlin, 286-298 (1987)). However, R-PIA and Cl-Ado analogs are actually more potent activators of A_1 adenosine receptors than of A_{2A} adenosine receptors and, thus, are likely to cause side effects due to activation of A_1 receptors on cardiac muscle and other tissues causing effects such as "heart block".

Linden et al. (U.S. Pat. No. 5,877,180) is based on the discovery that inflammatory diseases may be effectively treated by the administration of drugs which are selective agonists of A_{2A} adenosine receptors, preferably in combination with a phosphodiesterase inhibitor. An embodiment of the Linden et al. invention provides a method for treating inflammatory diseases by administering an effective amount of an A_{2A} adenosine receptor of the following formula:



wherein X is a group selected from the group consisting of $-OR^1$, $-NR^2R^3$, and $-NH-N=R^4$;

wherein R^1 is C_{1-4} -alkyl; C_{1-4} -alkyl substituted with one or more C_{1-4} -alkoxy groups, halogens (fluorine, chlorine, or bromine), hydroxy groups, amino groups, mono(C_{1-4} -alkyl)amino groups, di(C_{1-4} -alkyl)amino groups, or C_{6-10} -aryl groups (wherein the aryl groups may be substituted with one or more halogens (fluorine, chlorine, or bromine), C_{1-4} -alkyl groups, hydroxy groups, amino groups, mono(C_{1-4} -alkyl)amino groups, or di(C_{1-4} alkyl)amino groups); C_{6-10} -aryl; or C_{6-10} -aryl substituted with one or more halogens (fluorine, chlorine, or bromine), hydroxy groups, amino groups, mono(C_{1-4} -alkyl)amino groups, or di(C_{1-4} -alkyl)amino groups, or C_{1-4} -alkyl groups;

one of R^2 and R^3 has the same meaning as R^1 and the other is hydrogen;

R^4 is a group having the formula:




15

wherein each of R^5 and R^6 independently may be hydrogen, C_{3-7} -cycloalkyl, or any of the meanings of R^1 , provided that R^5 and R^6 are not both hydrogen; and


R is $-CH_2OH$, $-CH_2H$, $-CO_2R^7$, or $-C(=O)NR^8R^9$; wherein R^7 has the same meaning as R^1 and wherein R^8 and R^9 have the same meanings as R^5 and R^6 and R^8 and R^9 may both be hydrogen.

In a preferred embodiment, the Linden et al. invention involves the administration of a Type IV phosphodiesterase (PDE) inhibitor in combination with the A_{2A} adenosine receptor agonist. The Type IV phosphodiesterase (PDE)

inhibitor can be racemic and optically active 4-(polyalkoxyphenyl)-2-pyrrolidones of the following formula:



- (disclosed and described in U.S. Patent No. 4,193,926) wherein R¹⁸ and R¹⁹ each are alike or different and are hydrocarbon radicals having up to 18 carbon atoms with at least one being other than methyl, a heterocyclic ring, or alkyl of 1-5 carbon atoms which is substituted by one or more of halogen atoms, hydroxy, carboxy, alkoxy, alkoxycarbonyl or an amino group; amino; R' is a hydrogen atom, alkyl, aryl or acyl; and X is an oxygen atom or a sulfur atom.
- 10 Rolipram is an example of a suitable Type IV phosphodiesterase or PDE inhibitor included within the above formula. Rolipram has the following structure:



Summary of the Invention

- 15 The present invention provides a method to protect mammalian tissue from the effects of the inflammatory response. This treatment is achieved by the administration of certain agonists of A_{2A} adenosine receptors, preferably in

combination with rolipram or rolipram derivatives that are Type IV phosphodiesterase or PDE inhibitors.

Accordingly, one object of the present invention is to provide a novel and improved method for treating the inflammatory response to pathological agents and conditions, such as trauma.

It is another object of the present invention to provide novel and improved compositions for the treatment of the inflammatory response and, in some cases, the underlying disease.

These and other objects, which will become better understood during the course of the following detailed description, have been achieved by the inventors' discovery of improved compositions and methods for effectively treating inflammatory conditions by administration of an agonist of an A_{2A} adenosine receptor optionally, in combination with rolipram or a rolipram derivative that is a Type IV phosphodiesterase (PDE) inhibitor.

Brief Description of the Drawings

A more complete appreciation of the invention and many of the attendant advantages thereof will be readily obtained as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings, wherein:

Figure 1 illustrates the relative potencies of adenosine analogs to modulate TNF_{α} -primed fMLP-stimulated polymorphonuclear cell (PMN) chemiluminescence as a measure of PMN production of oxidative products (0, no TNF_{α} ; Δ , WRC-0474[SHA 211] + TNF_{α} ; \square , GCS 21680 + TNF_{α} ; and \blacktriangle , adenosine + TNF_{α});

Figure 2 illustrates the synergistic effect of WRC-0474[SHA 211] and 4-(3-cyclopentylloxy-4-methoxyphenyl)-2-pyrrolidone (rolipram) in inhibiting TNF_{α} -primed (10 U/ml), fMLP-stimulated (100 nM) PMN superoxide production: 0, no 4-(3-cyclopentylloxy-4-methoxyphenyl)-2-pyrrolidone; \blacktriangle , 3 nM 4-(3-cyclopentylloxy-4-methoxyphenyl)-2-pyrrolidone; \square , 30 nM 4-(3-cyclopentylloxy-4-methoxyphenyl)-2-pyrrolidone; and, 300 nM 4-(3-cyclopentylloxy-4-methoxyphenyl)-2-pyrrolidone;

Figure 3 illustrates the synergistic effect of WRC-0474[SHA 211] and rolipram in inhibiting TNF_{α} -stimulated adherent PMN superoxide release;

Figure 4 illustrates the effect of WRC-0474[SHA 211] and rolipram on TNF α -stimulated PMN adherence to a fibrinogen coated surface;

Figure 5 illustrates synergy between A_{2A} adenosine receptor agonists and Rolipram in inhibition superoxide release from TNF α -stimulated adherent
5 human neutrophils;

Figure 6 illustrates the effects of WRC-0470 and rolipram on the oxidative activity of neutrophils in whole blood;

Figure 7 illustrates the effects of WRC-0470 and rolipram on the release of TNF α from adherent human monocytes and that this activity is dependent on
10 binding of the adenosine agonist to A_{2A} adenosine receptors.

Figure 8 illustrates the effect of WRC-0470 on white blood cell pleocytosis in rats.


Figure 9 illustrates the effect of WRC-0470 on blood-brain-barrier permeability in rats;

15 Figure 10 illustrates the effect of rolipram on white blood cell pleocytosis in rats; and

Figure 11 illustrates the combined effect of WRC-0470 and rolipram on white blood cell pleocytosis in rats.

Detailed Description of the Preferred Embodiments

20 Thus, in a first embodiment, the present invention provides a method comprising treating the inflammatory response in a mammal in need of such treatment by administering an effective amount of a compound of formula (I):



wherein X is a group selected from the group consisting of -OR¹, -NR²R³, -C \equiv C-
25 Z and -NH-N=R⁴;

each Y is individually H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl or phenyl
C₁-C₃ alkyl;

- R^1 is (a) C_{1-4} -alkyl; (b) C_{1-4} -alkyl substituted with one or more C_{1-4} -alkoxy groups, halogens (fluorine, chlorine, or bromine), hydroxy groups, amino groups, mono(C_{1-4} -alkyl)amino groups, di(C_{1-4} -alkyl)amino groups, or C_{6-10} -aryl groups wherein the aryl groups may be substituted with one or more halogens (fluorine, chlorine, or bromine), C_{1-4} -alkyl groups, hydroxy groups, amino groups, mono(C_{1-4} -alkyl)amino groups, or di(C_{1-4} -alkyl)amino groups); (c) C_{6-10} -aryl; or (d) C_{6-10} -aryl substituted with one or more halogens (fluorine, chlorine, or bromine), hydroxy groups, amino groups, mono(C_{1-4} -alkyl)amino groups, di(C_{1-4} -alkyl)amino groups, or C_{1-4} -alkyl groups;
- one of R^2 and R^3 has the same meaning as R^1 and the other is hydrogen; or R^4 is a group having the formula (II)




- wherein each of R^5 and R^6 independently may be hydrogen, C_{3-7} -cycloalkyl, or any of the meanings of R^1 , provided that R^5 and R^6 are not both hydrogen;
- R is CH_2OH , CH_3 , CO_2R^7 or $C(=O)NR^8R^9$ wherein R^7 has the same meaning as R^2 and wherein R^8 and R^9 have the same meanings as R^5 and R^6 , or R^8 and R^9 are both H;

Z has one of the following meanings:

- a) C_6-C_{10} aryl, optionally substituted with one to three halogen atoms, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_2-C_6 alkoxy carbonyl, C_2-C_6 alkoxyalkyl, C_1-C_6 alkylthio, thio, CHO, cyanomethyl, nitro, cyano, hydroxy, carboxy, C_2-C_6 acyl, amino C_1-C_3 monoalkylamino, C_2-C_6 dialkylamino, methylenedioxy or aminocarbonyl;
- b) a group of formula $-(CH_2)_m$ -Het wherein m is 0 or an integer from 1 to 3 and Het is 5 or 6 membered heterocyclic aromatic or non-aromatic ring,
- optionally benzocondensed, containing 1 to 3 heteroatoms selected from nonperoxide oxygen, nitrogen or sulphur, linked through a carbon atom or through a nitrogen atom;

c) C₃-C₇ cycloalkyl optionally containing insaturations or C₂-C₄ alkenyl;



R¹⁰ is hydrogen, methyl or phenyl;

R¹² is hydrogen, C₁-C₆ linear or branched alkyl, C₅-C₆ cycloalkyl or C₃-C₇ cycloalkenyl, phenyl-C₁-C₂-alkyl or R¹⁰ and R¹², taken together, form a 5 or 6-membered carbocyclic ring or R³ is hydrogen and R² and R⁴, taken together, form an oxo group or a corresponding acetalic derivative;

R¹¹ is OH, NH₂ dialkylamino, halogen, cyano;

n is 0 or 1 to 4; or

e) C₁-C₁₆ alkyl, optionally comprising 1-2 double bonds, O, S or NY; or a pharmaceutically acceptable salt thereof.

Examples of suitable C₆₋₁₀-aryl groups include phenyl and naphthyl.

Preferably, in the compound of formula (I), X is a group of the formula


(III)



wherein n is an integer from 1-4, preferably 2, and Ar is a phenyl group, tolyl group, naphthyl group, xylyl group, or mesityl group. Most preferably Ar is a para-tolyl group and n=2.

Preferably, in the compound of formula (I), X is a group of the formula

(IV)



wherein Cy is a C₃₋₇-cycloalkyl group, preferably cyclohexyl or a C₁₋₄ alkyl group, preferably isopropyl.





Preferably, in the compound of formula (I), X is a group of the formula

(V)




wherein Z is C₃-C₁₆ alkyl, hydroxy C₂-C₆ alkyl or (phenyl) (hydroxymethyl).

Specific examples of such compounds of formula (I) include WRC-0470, WRC-0474 [SHA 211], WRC-0090 and WRC-0018, shown below:



and




Wherein the H on CH₂OH can optionally be replaced by ethylaminocarbonyl. Of these specific examples, WRC-0474[SHA 211] and WRC-0470 are particularly preferred.

- Such compounds may be synthesized as described in: Olsson et al. (U.S. Pat. Nos. 5,140,015 and 5,278,150); Cristalli (U.S. Pat. No. 5,593,975); Miyasaka et al. (U.S. Pat. No. 4,956,345); Hutchinson, A. J. et al., *J. Pharmacol. Exp. Ther.*, **251**, 47 (1989); Olsson, R. A. et al., *J. Med. Chem.*, **29**, 1683 (1986); Bridges, A. J. et al., *J. Med. Chem.*, **31**, 1282 (1988); Hutchinson, A. J. et al., *J. Med. Chem.*, **33**, 1919 (1990); Ukeeda, M. et al., *J. Med. Chem.*, **34**, 1334 (1991); Francis, J. E. et al., *J. Med. Chem.*, **34**, 2570 (1991); Yoneyama, F. et al., *Eur. J. Pharmacol.*, **213**, 199-204 (1992); Peet, N. P. et al., *J. Med. Chem.*, **35**, 3263 (1992); and Cristalli, G. et al., *J. Med. Chem.*, **35**, 2363 (1992); all of which are incorporated herein by reference.

- The present method also includes the administration of a Type IV phosphodiesterase (PDE) inhibitor in combination with the compound of formula (I). Examples of Type IV phosphodiesterase (PDE) inhibitors include those disclosed in U.S. Patent No. 4,193,926, and WO 92-079778, and Molnar-Kimber, K. L. et al., *J. Immunol.*, **150**, 295A (1993), all of which are incorporated herein by reference.

- Specifically, the suitable Type IV phosphodiesterase (PDE) inhibitors include racemic and optically active 4-(polyalkoxyphenyl)-2-pyrrolidones of general formula (V)



(V)

- (disclosed and described in U.S. Patent No. 4,193,926) wherein R¹⁸ and R¹⁹ each are alike or different and are hydrocarbon radicals having up to 18 carbon atoms with at least one being other than methyl, a heterocyclic ring, or alkyl of 1-5 carbon atoms which is substituted by one or more of halogen atoms, hydroxy, carboxy, alkoxy, alkoxycarbonyl or an amino group or amino.

Examples of hydrocarbon R¹⁸ and R¹⁹ groups are saturated and unsaturated, straight-chain and branched alkyl of 1-18, preferably 1-5, carbon atoms, cycloalkyl and cycloalkylalkyl, preferably 3-7 carbon atoms, and aryl and aralkyl, preferably of 6-10 carbon atoms, especially monocyclic.

5 Examples of alkyl are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, 2-methylbutyl, 2,2-dimethylpropyl, hexyl, heptyl, octyl, nonyl, 1,2-dimethylheptyl, decyl, undecyl, dodecyl and stearyl, with the proviso that when one of R¹⁸ and R¹⁹ is methyl, the other is a value other than methyl. Examples of unsaturated alkyl groups are alkenyl and alkynyl, e.g., vinyl, 1-
10 propenyl, 2-propenyl, 2-propynyl and 3-methyl-2-propenyl.

Examples of cycloalkyl and cycloalkylalkyl which preferably contain a total of 3-7 carbon atoms are cyclopropyl, cyclopropylmethyl, cyclopentyl and cyclohexyl.

15 Examples of aryl and aralkyl are phenyl and benzyl, which are preferred, and tolyl, xylyl, naphthyl, phenethyl and 3-phenylpropyl.

Examples of heterocyclic R¹⁸ and R¹⁹ groups are those wherein the heterocyclic ring is saturated with 5 or 6 ring members and has a single O, S or N atom as the hetero atom, e.g., 2- and 3-tetrahydrofuryl, 2- and 3-tetrahydropyranyl, 2- and 3-tetrahydrothiophenyl, pyrrolidino, 2- and 3-
20 pyrrolidyl, piperidino, 2-, 3- and 4-piperidyl, and the corresponding N-alkylpyrrolidyl and piperidyl wherein alkyl is of 1-4 carbon atoms. Equivalents are heterocyclic rings having fewer or more, e.g., 4 and 7, ring members, and one or more additional hetero atoms as ring members, e.g., morpholino, piperazino and N-alkylpiperazino.

25 Examples of substituted alkyl R¹⁸ and R¹⁹ groups, preferably of 1-5 carbon atoms, are those mono- or polysubstituted, for example, by halogen, especially fluorine, chlorine and bromine. Specific examples of such halogen-substituted alkyl are 2-chloroethyl, 3-chloropropyl, 4-bromobutyl, difluoromethyl, trifluoromethyl, 1,1,2-trifluoro-2-chloroethyl, 3,3,3-trifluoropropyl, 2,2,3,3,3-pentafluoropropyl and 1,1,1,3,3,3-hexafluoro-2-propyl.
30 Examples of other suitable substituents for such alkyl groups are hydroxy groups, e.g., 2-hydroxyethyl or 3-hydroxypropyl; carboxy groups, e.g., carboxymethyl or carboxyethyl; alkoxy groups, wherein each alkoxy group

contains 1-5 carbon atoms, e.g., ethoxymethyl, isopropoxymethyl, 2-methoxyethyl, 2-isopropoxyethyl, 2-butoxyethyl, 2-isobutoxyethyl, and 3-pentoxypentyl.

Also suitable as preferably terminal-positioned substituents on alkyl groups of 1-5 carbon atoms are alkoxy carbonyl of 1-5 carbon atoms in the alkoxy group. Examples of such alkoxy carbonyl substituted alkyl-groups are ethoxycarbonylmethyl and 2-butoxycarbonylethyl.

Alkyl groups of 1-5 carbon atoms can also be substituted, e.g., in the β , γ and preferably terminal position with amino groups wherein the nitrogen atom optionally is mono- or disubstituted by alkyl, preferably of 1-5 carbon atoms, or is part of a 4- to 7- membered ring.

Rolipram and its analogues are specific examples of preferred Type IV phosphodiesterase inhibitors.

Among the inflammatory responses that can be treated (including inhibited, blocked or treated prophylactically) with a compound of formula (I), optionally with a Type IV PDE inhibitor, are inflammation due to

(a) autoimmune stimulation (autoimmune diseases), such as lupus erythematosus, multiple sclerosis, infertility from endometriosis, gout, type I diabetes mellitus including the destruction of pancreatic islets leading to diabetes and the inflammatory consequences of diabetes, including leg ulcers, Crohn's disease, ulcerative colitis, inflammatory bowel disease, osteoporosis and rheumatoid arthritis;

(b) allergic diseases such as asthma, hay fever, rhinitis, vernal conjunctivitis and other eosinophil-mediated conditions;

(c) skin diseases such as psoriasis, contact dermatitis, eczema, infectious skin ulcers, open wounds, cellulitis;

(d) infectious diseases including sepsis, septic shock, encephalitis, infectious arthritis, endotoxic shock, gram negative shock, Jarisch-Herxheimer reaction, shingles, toxic shock, cerebral malaria, bacterial meningitis, acute respiratory distress syndrome (ARDS), lyme disease, HIV infection, (TNF α -enhanced HIV replication, TNF α inhibition of reverse transcriptase inhibitor activity);

(e) wasting diseases: cachexia secondary to cancer and HIV;

(f) organ, tissue or cell transplantation (e.g., bone marrow, cornea, kidney, lung, liver, heart, skin, pancreatic islets) including transplant rejection, and graft versus host disease;

(g) adverse effects from drug therapy, including adverse effects from amphotericin B treatment, adverse effects from immunosuppressive therapy, e.g., interleukin-2 treatment, adverse effects from OKT3 treatment, adverse effects from GM-CSF treatment, adverse effects of cyclosporine treatment, and adverse effects of aminoglycoside treatment, stomatitis and mucositis due to immunosuppression;

(h) cardiovascular conditions including circulatory diseases induced or exacerbated by an inflammatory response, such as ischemia, atherosclerosis, peripheral vascular disease, restenosis following angioplasty, inflammatory aortic aneurysm, vasculitis, stroke, spinal cord injury, congestive heart failure, hemorrhagic shock, ischemia/reperfusion injury, vasospasm following subarachnoid hemorrhage, vasospasm following cerebrovascular accident, pleuritis, pericarditis, and the cardiovascular complications of diabetes; and
(i) dialysis, including pericarditis, due to peritoneal dialysis.

Of particular interest and efficacy is the use of the present compounds to treat inflammatory responses due to organ, tissue or cell transplantation, i.e., the transplantation of allogeneic or xenogeneic tissue into a mammalian recipient, inflammation due to autoimmune diseases and inflammatory responses due to circulatory pathologies such as ischemia, and the treatment thereof, including angioplasty, stent placement, shunt placement or grafting.

While many of the compounds of formula (I) are vasodilators, and thus have been reported as useful to treat ischemia, atherosclerosis, hypertension, thrombus and the like, the anti-inflammatory activity of these compounds has not heretofore been suggested.

The invention also includes a method for binding a compound of formula (I) to designated A_{2A} adenosine receptor sites comprising said receptors, *in vivo* or *in vitro*, with an amount of a compound of formula (I) effective to bind to said receptors. Tissue or cells comprising ligand bound receptor sites can be used to measure the selectivity of test compounds for specific receptor subtypes, or can be used as a tool to identify potential therapeutic agents for the treatment

of diseases or conditions associated with receptor site activation, by contacting said agents with said ligand-receptor complexes, and measuring the extent of displacement of the ligand and/or binding of the agent.

The exact dosage of the compound of formula (I) to be administered will, of course, depend on the size and condition of the patient being treated, the exact condition being treated, and the identity of the particular compound of formula (I) being administered. However, a suitable dosage of the compound of formula (I) is 0.5 to 100 $\mu\text{g/kg}$ of body weight, preferably 1 to 10 $\mu\text{g/kg}$ of body weight. Typically, the compound of formula (I) will be administered from 1 to 8, preferably 1 to 4, times per day.

The preferred mode of administration of the compound of formula (I) may also depend on the exact condition being treated. However, most typically, the mode of administration will be oral, topical, intravenous, parenteral, subcutaneous, or intramuscular injection.

Of course, it is to be understood that the compound of formula (I) may be administered in the form of a pharmaceutically acceptable salt. Examples of such salts include acid addition salts. Preferred pharmaceutically acceptable addition salts include salts of mineral acids, for example, hydrochloric acid, sulfuric acid, nitric acid, and the like; salts of monobasic carboxylic acids, such as, for example, acetic acid, propionic acid, and the like; salts of dibasic carboxylic acids, such as maleic acid, fumaric acid, oxalic acid, and the like; and the salts of tribasic carboxylic acids, such as, carboxysuccinic acid, citric acid, and the like. In the compounds of formula (I) in which R is $-\text{CO}_2\text{H}$, the salt may be derived by replacing the acidic proton of the $-\text{CO}_2\text{H}$ group with a cation such as Na^+ , K^+ , NH_4^+ mono-, di-, tri-, or tetra(C_{1-4} -alkyl)ammonium, or mono-, di-, tri-, or tetra(C_{2-4} alkanol) ammonium.

Preferred pharmaceutically acceptable addition salts include salts of mineral acids, for example, hydrochloric acid, sulfuric acid, nitric acid, and the like; salts of monobasic carboxylic acids, such as, for example, acetic acid, propionic acid, and the like; salts of dibasic carboxylic acids, such as maleic acid, fumaric acid, oxalic acid, and the like; and salts of tribasic carboxylic acids, such as, carboxysuccinic acid, citric acid, and the like.

It is also to be understood that many of the compounds of formula (I) may exist as various isomers, enantiomers, and diastereomers and that the present invention encompasses the administration of a single isomer, enantiomer, or diastereomer in addition to the administration of mixtures of isomers, enantiomers, or diastereomers.

The compounds of formula (I) can be administered orally, for example, with an inert diluent with an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purposes of oral therapeutic administration, the compounds can be incorporated with excipients and used in the form of tablets, troches, capsules, elixers, suspensions, syrups, waters, chewing gums, and the like. These preparations should contain at least 0.5% by weight of the compound of formula (I), but the amount can be varied depending upon the particular form and can conveniently be between 4.0% to about 70% by weight of the unit dosage. The amount of the compound of formula (I) in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form contains between about 30 μg and about 5 mg, preferably between 50 to 500 μg , of active compound.

Tablets, pills, capsules, troches, and the like can contain the following ingredients: a binder, such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient, such as starch or lactose; a disintegrating agent, such as alginic acid, Primogel, corn starch, and the like; a lubricant, such as magnesium stearate or Sterotes; a glidant, such as colloidal silicon dioxide; a sweetening agent, such as sucrose, saccharin or aspartame; or flavoring agent, such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule it can contain, in addition to the compound of formula (I), a liquid carrier, such as a fatty oil.

Other dosage unit forms can contain other materials that modify the physical form of the dosage unit, for example, as coatings. Thus, tablets or pills can be coated with sugar, shellac, or other enteric coating agents. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and preservatives, dyes, colorings, and flavors. Materials used in preparing these

compositions should be pharmaceutically pure and non-toxic in the amounts used.

For purposes of parenteral therapeutic administration, the compounds of formula (I) can be incorporated into a solution or suspension. These preparations should contain at least 0.1% of the aforesaid compound, but may be varied between 0.5% and about 50% of the weight thereof. The amount of active compound in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 30 μ g to 5 mg, preferably between 50 to 500 μ g, of the compound of formula (I).

Solutions or suspensions of the compounds of formula (I) can also include the following components: a sterile diluent, such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents, such as benzyl alcohol or methyl parabens; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates or phosphates; and agents for the adjustment of tonicity, such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Effective amounts of the Type IV phosphodiesterase inhibitor can be administered to a subject by any one of various methods, for example, orally as in a capsule or tablets, topically, or parenterally in the form of sterile solutions. The Type IV phosphodiesterase inhibitors, while effective themselves, can be formulated and administered in the form of their pharmaceutically acceptable addition salts for purposes of stability, convenience of crystallization, increased solubility, and the like.

The Type IV phosphodiesterase may be administered in the form of a pharmaceutical composition similar to those described above in the context of the compound of formula (I).

While dosage values will vary with the specific disease condition to be alleviated, good results are achieved when the Type IV phosphodiesterase inhibitor is administered to a subject requiring such treatment as an effective oral, parenteral or intravenous dose as described below.

For oral administration, the amount of active agent per oral dosage unit usually is 0.1-20 mg, preferably 0.5-10 mg. The daily dosage is usually 0.1-50 mg, preferably 1-30 mg p.o. For parenteral application, the amount of active agent per dosage unit is usually 0.005-10 mg, preferably 0.01-5 mg. The daily
5 dosage is usually 0.01-20 mg, preferably 0.02-5 mg i.v. or i.m.

With topical administration, dosage levels and their related procedures would be consistent with those known in the art, such as those dosage levels and procedures described in U.S. Patent No. 5,565,462 to Eitan et al., which is incorporated herein by reference.

10 It is to be understood, however, that for any particular subject, specific dosage regimens should be adjusted to the individual need and the professional judgment of the person administering or supervising the administration of the Type IV phosphodiesterase inhibitor. In some cases, the compound of formula (I) will be administered for an extended period of time following the
15 inflammatory insult, even chronically. It is to be further understood that the dosages set forth herein are exemplary only and that they do not, to any extent, limit the scope or practice of the present invention.

In a particularly preferred embodiment, the compound of formula (I) and the Type IV phosphodiesterase inhibitor are coadministered together in a single
20 dosage unit. The compound of formula (I) and the Type IV phosphodiesterase inhibitor may be administered in the same type of pharmaceutical composition as those described above in the context of the compound of formula (I).

By coadministering a Type IV phosphodiesterase inhibitor with the agonist of the A_{2A} adenosine receptor, it is possible to dramatically lower the
25 dosage of the A_{2A} adenosine receptor agonist and the Type IV phosphodiesterase inhibitor due to a synergistic effect of the two agents. Thus, in the embodiment involving coadministration of the A_{2A} adenosine receptor agonist with the Type IV phosphodiesterase inhibitor, the dosage of the A_{2A} adenosine receptor agonist may be reduced by a factor of 5 to 10 from the dosage used when no Type IV
30 phosphodiesterase inhibitor is administered. This reduces the possibility of side effects.

The present invention will now be described in more detail in the context of the coadministration of WRC-0470, WRC-0474[SHA 211], WRC-0090 or

WRC-0018 and rolipram. However, it is to be understood that the present invention may be practiced with other compounds of formula (I) and other Type IV phosphodiesterase inhibitors of formula (V).

- The present studies establish that anti-inflammatory doses have no toxic effects in animals; the effect of WRC-0470 to inhibit neutrophil activation is synergistic with rolipram; and intravenous infusion of WRC-0470 profoundly inhibits extravasation of neutrophils in an animal model of inflammation, an action also synergistic with rolipram. Further, the present studies establish that activation of A_{2A} receptors on human monocytes strongly inhibits TNF α (an inflammatory cytokine) release. This mechanism further contributes to the anti-inflammatory action of the A_{2A} adenosine receptor agonists of the present invention.
- 5 effects in animals; the effect of WRC-0470 to inhibit neutrophil activation is synergistic with rolipram; and intravenous infusion of WRC-0470 profoundly inhibits extravasation of neutrophils in an animal model of inflammation, an action also synergistic with rolipram. Further, the present studies establish that activation of A_{2A} receptors on human monocytes strongly inhibits TNF α (an inflammatory cytokine) release. This mechanism further contributes to the anti-inflammatory action of the A_{2A} adenosine receptor agonists of the present invention.
- 10 inflammatory cytokine) release. This mechanism further contributes to the anti-inflammatory action of the A_{2A} adenosine receptor agonists of the present invention.

- Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.
- 15 illustration of the invention and are not intended to be limiting thereof.

EXAMPLES

Materials and Methods

- Materials.** f-Met-Leu-Phe(fMLP), luminol, and trypan blue were from Sigma Chemical. Ficoll-Hypaque was purchased from Flow Laboratories (McLean, A) and Los Alamos Diagnostics (Los Alamos, NM). Hanks balanced salt solution (HBSS), and limulus amebocyte lysate assay kit were from Whittaker Bioproducts (Walkersville, MD). Human serum albumin (HSA) was from Cutter Biological (Elkhart, IN). Recombinant human tumor necrosis factor-alpha was supplied by Dianippon Pharmaceutical Co. Ltd. (Osaka, Japan).
- 20 (McLean, A) and Los Alamos Diagnostics (Los Alamos, NM). Hanks balanced salt solution (HBSS), and limulus amebocyte lysate assay kit were from Whittaker Bioproducts (Walkersville, MD). Human serum albumin (HSA) was from Cutter Biological (Elkhart, IN). Recombinant human tumor necrosis factor-alpha was supplied by Dianippon Pharmaceutical Co. Ltd. (Osaka, Japan).
- 25 ZM241385 was a gift of Dr. Simon Poucher, Zeneca Pharmaceuticals (Cheshire, England).

- Leukocyte Preparation:** Purified PMN (~98% PMN and >95% viable by trypan blue exclusion) containing <1 platelet per 5 PMN and <50 pg/ml endotoxin (limulus amebocyte lysate assay) were obtained from normal
- 30 heparinized (10 Units/ml) venous blood by a one-step Ficoll-Hypaque separation procedure (Ferrante, A. et al., *J. Immunol. Meth.*, 36, 109 (1980)). Residual RBC were lysed by hypotonic lysis with iced 3 ml 0.22% sodium chloride solution for 45 seconds followed by 0.88 ml of 3% sodium chloride solution.

Chemiluminescence. Luminol-enhanced chemiluminescence, a measure of neutrophil oxidative activity, is dependent upon both superoxide production and mobilization of the granule enzyme myeloperoxidase. The light is emitted from unstable high-energy oxygen species generated by activated neutrophils.

- 5 Purified PMN ($5 \times 10^5/\text{ml}$) were incubated in HBSS containing 0.1% human serum albumin (1 ml) with or without adenosine, adenosine analogs, and $\text{TNF}\alpha$ (1 U/mL) for 30 minutes at 37°C in a shaking water bath. Then luminol (1×10^{-4} M) enhanced f-met-leu-phe (1 μM) stimulated chemiluminescence was read with a Chronolog Photometer (Chrono-log Corp., Havertown, PA) at 37°C for 8 min.
- 10 Chemiluminescence is reported as relative peak light emitted (= height of the curve) compared to samples with TNF and without adenosine or adenosine analogs. WRC-0474[SHA 211] was 10 times more potent than either adenosine (ADO) or CGS21680 in decreased $\text{TNF}\alpha$ -primed f-met-leu-phe-stimulated PMN chemiluminescence (see Figure 1).

- 15 Synergy of A_2A Adenosine Receptor Agonist and Phosphodiesterase Inhibitors. The synergy between WRC-0474[SHA 211] and 4-(3-cyclopentyl-4-methoxyphenyl)-2-pyrrolidone (rolipram) was examined by measuring the effect of combined WRC-0474[SHA 211] and rolipram on $\text{TNF}\alpha$ -primed f-met-leu-phe-stimulated suspended neutrophil superoxide release and on
- 20 the oxidative burst of neutrophils adhering to matrix proteins (in this model, the PMN oxidative burst is enhanced by small concentrations of $\text{TNF}\alpha$ [e.g., 1 U/ml] when added prior to the addition of a second stimulus such as the peptide f-met-leu-phe).

- Suspended PMN Superoxide Release. Human PMN ($1 \times 10^6/\text{ml}$) from
- 25 Ficoll-Hypaque separation were primed for 30 minutes (37°C) with or without rh TNF (10 U/ml), with adenosine deaminase (1 U/ml), and with or without 4-(3-cyclopentyl-4-methoxyphenyl)-2-pyrrolidone and SHA 211. Cytochrome c (120 μM), catalase (0.062 mg/ml) and FMLP (100 nM) were added and the samples incubated for 10 minutes more at 37°C . SOD (200 U/ml) was added to
- 30 matched samples. The samples were iced and centrifuged ($2000 \text{ g} \times 10$ minutes). The optical density of the supernatants was read at 550 nm against the matched SOD samples, and the nmoles of SOD-inhibitable superoxide released in 10 minutes were calculated.

A synergistic effect of WRC-0474[SHA 211] and rolipram in decreasing the TNF α -primed fMLP-stimulated PMN oxidative burst was observed (see Figure 2).

TNF α -stimulated superoxide release of PMN adherent to a matrix protein (fibrinogen) coated surface. Human PMN (1×10^6 /ml) from Ficoll-Hypaque separation were incubated for 90 minutes in 1 ml of Hanks balanced salt solution containing 0.1% human serum albumin, cytochrome c (120 μ M), and catalase (0.062 mg/ml) in the presence and absence of rhTNF (1 U/ml), WRC-0474[SHA 211] (10 nM) and rolipram (100 nM) in a tissue culture well which had been coated overnight with human fibrinogen. SOD (200 U/ml) was added to matched samples. The supernatants were iced and centrifuged ($2000 \text{ g} \times 10$ minutes) to remove any remaining suspended cells, and the optical density of the supernatants were read at 550 nm against the matched SOD samples, and the nmoles of SOD-inhibitable superoxide released in 90 minutes were calculated.

A synergistic effect of WRC-0474[SHA 211] and rolipram in decreasing the TNF α -stimulated release of superoxide from PMN adherent to fibrinogen was observed (see Figure 3).

Effect of WRC-0474[SHA 211] with and without rolipram on TNF α -Stimulated PMN Adherence to a Fibrinogen-Coated Surface. Cronstein et al., *J. Immunol.*, 148, 2201 (1992) reported that adenosine binding to A₁ receptors increases PMN adherence to endothelium and matrix proteins and binding to A₂ receptors decreases adherence to these surfaces when the PMN are stimulated with fMLP. Despite this, others have failed to see much of an effect of adenosine (10 μ M) on TNF α -stimulated PMN adherence to matrix proteins. In contrast, adenosine dramatically decreases the oxidative burst of TNF α -stimulated PMN adhering to matrix proteins (DeLa Harpe, J., *J. Immunol.*, 143, 596 (1989)). The experiments described above establish that WRC-0474[SHA 211] decreases TNF-stimulated oxidative activity of PMN adhering to fibrinogen, especially when combined with rolipram.

PMN adherence to fibrinogen was measured as follows as adapted from Hanlon, *J. Leukocyte Biol.*, 50, 43 (1991). Twenty-four well flat-bottomed tissue culture plates were incubated (37°C) overnight with 0.5 ml of fibrinogen (5 mg/ml) dissolved in 1.5% NaHCO₃. The plates were emptied and each well

washed 2X with 1 ml of normal saline. The wells were then filled with 1 ml of HBSS-0.1% human serum albumin containing PMN ($1 \times 10^6/\text{ml}$) with and without rhTNF α (1 U/ml), adenosine deaminase (ADA) (1 U/ML), WRC-0474[SHA 211] (10 nM), CGS21680 (30 nM), adenosine (100 nM) and rolipram (100 nM). The plates were incubated for 90 minutes at 37°C in 5% CO₂. Following incubation the tissue culture wells were washed free of non-adherent cells with normal saline. The adherent monolayer of PMN was lysed with 0.1% triton-X, the amount of lactic dehydrogenase (LDH) released from the monolayer assayed (LDH kit, Sigma Co., St. Louis, MO), and compared to a standard curve relating the LDH content to PMN numbers. The results are shown in Figure 4.

As a comparison to WRC-0474[SHA 211] (at only 10 nM), CGS21680 (30 nM) decreased TNF-stimulated adherence in the presence of ADA from 38% to 30% adhered ($p = .004$) (see Fig. 4), and ten times as much adenosine (100 nM) decreased adherence to 28% adhered ($p = .009$ compared to TNF in the presence of ADA).

Additional effects of adenosine A_{2A} agonists on adherent human neutrophil oxidative activity. The bioactivity of test compounds WRC-0474[SHA 211], WRC-0470, WRC-0090 and WRC-0018 were evaluated according to the following method modified from Sullivan, G. W. et al., *Int. J. Immunopharmacol*, 17, 793-803 (1995). Neutrophils ($1 \times 10^6/\text{ml}$ from Ficoll-Hypaque separation were incubated for 90 minutes in 1 ml of Hanks balanced salt solution containing 0.1% human serum albumin, cytochrome c (120 μM) and catalase (0.062 mg/ml) in the presence and absence of rhTNF α (1 U/ml), WRC-0474[SHA 211], WRC-0470, WRC-0090 and WRC-0018 (3-300 nM), and rolipram (100 nM) in a tissue culture well which had been coated overnight with human fibrinogen. The supernatants were iced and centrifuged (200 g \times 10 min) to remove any remaining suspended cells, and the optical densities of the supernatants were read at 550 nm against matched superoxide dismutase (SOD) (200 U/ml) samples. The nmoles of SOD = inhabitable superoxide released in 90 min were calculated.

Figure 5 shows synergy between A_{2A} adenosine agonists and rolipram in inhibiting TNF α -stimulated adherent PMN oxidative activity ($p < 0.05$). WRC-

- 0474[SHA 211] (30-300 nM), WRC-0470 (300 nM), WRC-0090 (300 nM) and WRC-0018 (300 nM) combined with rolipram synergistically decreased superoxide release ($p < 0.05$). All four compounds had some activity in the presence of rolipram. WRC-0474[SHA 211] and WRC-0470 were the most active. Nanomolar concentrations of WRC-0474[SHA 211] resulted in biphasic activity. All compounds were synergistic with rolipram to decrease TNF α -stimulated adherent PMN oxidative activity.

- PMN degranulation (adherent cells). The following methods were adapted from Sullivan, G. W. and G. L. Mandell, *Infect. Immun.*, **30**, 272-280 (1980). Neutrophils (3.1×10^6 /ml) from Ficoll-Hypaque separation were incubate for 120 minutes in 1 ml of Hanks balanced salt solution containing 0.1% human serum albumin, \pm rh TNF α (10 U/ml), \pm WRC-0470 (3-300 nM), and \pm rolipram (30 nM) in a tissue culture well which had been coated overnight with human fibrinogen. The supernatant fluids with any suspended neutrophils were harvested following incubation, centrifuged ($2000 \times g$ for 10 min) to remove any suspended cells and the cell-free supernatants frozen. Release of lysozyme, a component of neutrophil primary and secondary granules was assayed. Lysis of a suspension of *Micrococcus lysodeikticus* by the "cell-free supernatant" was measured by spectrophotometric analysis (540 nm) to determine the amount of release of granule contents to the surrounding medium.

- Results showed that WRC-0470 (300 nM) with rolipram (300 nM) significantly decreased TNF α -stimulated adherent neutrophil degranulation 67%; $P=0.027$. The data indicate that in addition to decreasing TNF α -stimulated PMN adherent and the oxidative burst of these adherent neutrophils, WRC-0470 also decreases degranulation activated PMN adhering to a biological surface.

- PMN oxidative activity in whole blood. The following methods were adapted from Rothe, G. A. et al., *J. Immunol. Meth.*, **138**, 133-135 (1991). Heparinized whole blood (0.8 ml) was incubated (37° ; 30 min) with adenosine deaminase (ADA, 1 U/ml), catalase (14,000 U/ml), \pm dihydrorhodamine 123, \pm WRC-0470 (3-300 nM), \pm rolipram (300 nM) and \pm TNF α (10 U/ml). The primed blood samples were stimulated with fMLP (15 min), then iced, the red blood cells lysed with FACS lysing solution (Becton-Dickinson, San Jose, CA), washed and the leukocytes resuspended in phosphate-buffered saline (PBS).

These samples containing mixed leukocytes were gated for neutrophils by forward and side scatter and the fluorescence of 10,000 neutrophils measured in the FL1 channel of a FACScan (Beckton-Dickinson) fluorescence-activated cell sorter.

- 5 The results are reported as relative mean fluorescence intensity in Figure 6 of the drawings. WRC-0470 decreased oxidative activity of $\text{TNF}\alpha$ -primed fMLP-stimulated neutrophils in whole blood and acted synergistically with rolipram. WRC-0470 (30-300 nM) decreased neutrophil oxidative activity synergistically with rolipram (300 nM) in samples stimulated with fMLP and in
10 blood samples primed with $\text{TNF}\alpha$ and then stimulated with fMLP.

- Production of $\text{TNF}\alpha$ by purified human adherent monocytes. A monocyte rich monolayer (> 95% monocytes) was prepared by incubating 1 ml of the mononuclear leukocyte fraction ($5 \times 10^5/\text{ml}$) from a Ficoll-Hypaque separation in wells of a 24 well tissue culture plate (1 hr; 37°C ; 5% CO_2). The
15 non-adherent leukocytes were removed by washing and culture medium added to the wells (1 ml RPMI 1640 containing 1.5 mM HEPES-1% autologous serum with penicillin and streptomycin (250 U/ml and 250 $\mu\text{g}/\text{ml}$, respectively) and ADA (1 U/ml) \pm WRC-0470 (30-100 nM), \pm endotoxin (10 ng/ml), \pm rolipram (300 nM) and \pm the adenosine $\text{A}_{2\text{A}}$ selective antagonist 4-(2-[7-amino-2-(2-
20 furyl)[1,2,4]-triazolo[2,3-a]-[1,3,5]triazinyl-amino]ethyl)-phenol (ZM241385) (50 nM). The samples were incubated for 4 hr (37°C ; 5% CO_2) and the supernatants harvested. Any suspended cells were removed by centrifugation and the cell-free samples frozen (-70°C). $\text{TNF}\alpha$ was assayed in the cell-free supernatants by an ELISA kit (Cistron Biotechnology, Pine Brook, NJ).

- 25 As shown in Figures 7A and 7B, WRC-0470 \pm rolipram decreased endotoxin-stimulated adherent monocyte production of $\text{TNF}\alpha$ ($P < 0.050$). As illustrated in Figure 7B, the $\text{A}_{2\text{A}}$ selective antagonist ZM241385 significantly inhibited the effect of WRC-0470 (300 nM) combined with rolipram (300 nM) ($p = 0.020$) on $\text{TNF}\alpha$ release from monocytes. Hence, WRC-0470 affects
30 $\text{TNF}\alpha$ -stimulated neutrophil activity and decreases endotoxin-stimulated $\text{TNF}\alpha$ production by monocytes.

Effects of WRC-0470 and rolipram on the extravasation of white blood cells in a rat model of inflammation. Adult wistar rats (approximately 200 g)

were anesthetized with intermuscular injections of ketamine and xylazine. Bacteria meningitis (BM) was introduced via intracisternal inoculation of either *E. coli* strain 026:B6LPS (200 ng), cytokines (IL-1 and TNF α , or LPS plus cytokines). The animals were then infused with rolipram and/or WRC-1470 over the duration of the experiment using a Harvard pump. CSF (cerebrospinal fluid) and blood was then sampled at 4 h post-inoculation and alterations in BBBP (blood-brain barrier permeability) and WBC (white blood cell) counts were determined. CSF and WBC concentrations were determined with standard hemacytometer methods. For assessment of % BBBP, rats were given an intravenous injection of 5 μ Ci 125I-labeled bovine serum albumin concomitant with intracisternal inoculation. Equal samples of CSF and blood were read simultaneously in a gamma counter and after subtraction of background radioactivity, % BBBP was calculated by the following formula: % BBBP = (cpm CSF/cpm blood) \times 100. All statistical tests were performed using Instat biostatistical software to compare the post-inoculation samples of experimental rats with the control rats. The statistical tests used to generate p-values were Student's t-test and ANOVA.

Results of the tests are reported in Figures 8 and 9. Infusion of WRC-0470 at a rate of 0.005-1.2 μ g/kg/hr inhibited pleocytosis ($p < 0.05$ as compared to control). The effect of WRC-0470 on BBBP is shown in Figure 9. A significant response is seen with a range of 0.01-0.015 μ g/kg/hr ($p < 0.05$ as compared to control). A rebound effect is noted with the administration of 1.2 μ g/kg/hr where % BBBP returned to control. Figure 10 shows the effect of rolipram on CSF pleocytosis in a range of 0-0.01 μ g/kg/hr with 0.01 μ g/kg/hr inhibiting 99% of the pleocytosis ($p < 0.05$). Rolipram at either 0.01 or 0.005 μ g/kg/hr showed significant inhibition of alterations of BBBP ($p < 0.05$), while a dose of 0.002 μ g/kg/hr had no significant effect.

The effect of a combination of rolipram and WRC-0470 on CSF WBC pleocytosis is illustrated in Figure 11. Rolipram (0.001 μ g/kg/hr) in combination with WRC-0470 (0.1 μ g/kg/hr) inhibited migration of WBC's (200 ± 70 WBC/ μ l) into the sub-arachnoid space (SAS) to a greater extent than did either rolipram ($1,670 \pm 1,273$ WBC/ μ l, $p < 0.050$) or WRC-0470 (600 ± 308 WBCs/ μ l, $p < 0.050$) alone. The data show a powerful inhibiting effect of

WRC-0470 and a synergy with rolipram to prevent inflammation in an animal model.


- Application of A_{2A} adenosine receptors with or without rolipram on balloon angioplasty and gene therapy. Balloon angioplasty is commonly used to
- 5 treat coronary artery stenosis. Restenosis following balloon angioplasty (BA) occurs in up to 40% of coronary interventions. Holmes et al., American Journal of Cardiology, 53, 77C-81C (1984). (40%). Restenosis results from a complex interaction of biologic processes, including (i) formation of platelet-rich thrombus; (ii) release of vasoactive and mitogenic factors causing migration and
- 10 proliferation of smooth muscle cells (SMC); (iii) macrophage and other inflammatory cell accumulation and foam cell (FC) formation; (iv) production of extracellular matrix; and (v) geometric remodeling. Recently the use of coronary stents and pharmacologic intervention using a chimeric antibody to block the integrin on platelets have been partially successful in limiting restenosis after
- 15 percutaneous coronary interventions in man. Topol et al., Lancet, 343, 881-886 (1994). Since inflammatory cell infiltration might be central to the response to injury, and restenotic process, and adenosine, activating via A_{2A} adenosine receptors, inhibits tissues inflammatory cell accumulation, we hypothesize that agonists of A_{2A} adenosine receptors \pm Type IV PDE inhibitors will reduce the
- 20 incidence of restenosis following balloon angioplasty.

- In addition, recent advances in local delivery catheters and gene delivery techniques raise the interesting and exciting possibility of administering genes locally into the vessel wall. Nabel et al., Science, 249, 1285-1288 (1990); Leclerc et al., Journal of Clinical Investigation, 90, 936-944 (1992). Adenoviral-
- 25 mediated gene transfer affords several advantages over other techniques. However, gene expression is only transient, and has been observed for 7-14 days with diminution or loss of expression by 28 days. Lack of persistence may result from host immune cytolytic responses directed against infected cells. The inflammatory response generated by the present generation of adenovirus results
- 30 in neointimal lesion formation and may thus offset the benefit of a therapeutic gene. Newman et al., Journal of Clinical Investigation, 96, 2955-2965 (1995). An A_{2A} adenosine receptor agonist \pm a Type IV phosphodiesterase inhibitor in combination with adenovirus may improve the efficiency of gene transfer.

Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.

What is Claimed:

1. A method of treating an inflammatory response, comprising administering to a mammal in need thereof an effective anti-inflammatory amount of agonist of an A_{2A} adenosine receptor.
2. The method of claim 1 further comprising administering the agonist in combination with an effective amount of a Type IV phosphodiesterase inhibitor.
3. The method of claim 1 or 2, wherein said agonist of an A_{2A} adenosine receptor has the formula (I).




- wherein X is a group selected from the group consisting of $-OR^1$, $-NR^2R^3$, $-C\equiv C-$ Z and $-NH-N=R^4$;

each Y is individually H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl or phenyl C₁-C₃ alkyl;

- R¹ is (a) C₁₋₄-alkyl; (b) C₁₋₄-alkyl substituted with one or more C₁₋₄-alkoxy, halogens (fluorine, chlorine, or bromine), hydroxy, amino, mono(C₁₋₄-alkyl)amino, di(C₁₋₄-alkyl)amino, or C₆₋₁₀-aryl wherein aryl may be substituted with one or more halogen, C₁₋₄-alkyl, hydroxy, amino, mono(C₁₋₄-alkyl)amino, or di(C₁₋₄-alkyl)amino; (c) C₆₋₁₀-aryl; or (d) C₆₋₁₀-aryl substituted with one or more halogen, hydroxy, amino, mono(C₁₋₄-alkyl)amino, di(C₁₋₄-alkyl)amino, or C₁₋₄-alkyl;
- one of R² and R³ has the same meaning as R¹ and the other is hydrogen;

R⁴ is a group having the formula:




wherein each of R⁵ and R⁶ independently may be hydrogen, C₃₋₇-cycloalkyl, or any of the meanings of R¹, provided that R⁵ and R⁶ are not both hydrogen;

R is CH₂OH, CH₃, CO₂R⁷ or C(=O)NR⁸R⁹; wherein R⁷ has the same meaning as R² and wherein R⁸ and R⁹ have the same meanings as R⁵ and R⁶, or R⁸ and R⁹ are both H;

Z has one of the following meanings:

- a) phenyl or naphthyl optionally substituted with one to three halogen atoms, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkoxycarbonyl, C₂-C₆ alkoxyalkyl, C₁-C₆ alkylthio, thio, CHO, cyanomethyl, nitro, cyano, hydroxy, carboxy, C₂-C₆ acyl, amino, C₁-C₃ monoalkylamino, C₂-C₆ dialkylamino, methylenedioxy; aminocarbonyl;
- b) a group of formula -(CH₂)_m-Het wherein m is 0 or an integer from 1 to 3 and Het is 5 or 6 membered heterocyclic aromatic or non-aromatic ring, optionally benzocondensed, containing 1 to 3 heteroatoms selected from nonperoxide oxygen, nitrogen or sulphur, linked through a carbon atom or through a nitrogen atom;

c) C₃-C₇ cycloalkyl optionally containing insaturations or C₂-C₄ alkenyl;



R¹⁰ is hydrogen, methyl or phenyl;




- 20 R¹² is hydrogen, C₁-C₆ linear or branched alkyl, C₅-C₆ cycloalkyl or C₃-C₇ cycloalkenyl, phenyl-C₁-C₂-alkyl or R¹⁰ and R¹², taken together, form a 5- or 6-membered carbocyclic ring or R³ is hydrogen and R² and R⁴, taken together, form an oxo group or a corresponding acetalic derivative;

R¹¹ is OH, NH₂ dialkylamino, halogen, cyano;


- 25 n is 0 or 1 to 4; or

e) C_1-C_{16} alkyl, optionally comprising 1-2 double bonds, O, S or NY; or a pharmaceutically acceptable salt thereof.


4. The method of claim 1 or 2, wherein said agonist of an A_{2A} adenosine
5 receptor is selected from the group consisting of:



and



5. The method of claim 2, wherein said Type IV phosphodiesterase inhibitor is a compound having formula (V):



(V)


5 wherein R^{18} and R^{19} each are alike or different and are hydrocarbon radicals having up to 18 carbon atoms with at least one being other than methyl, a heterocyclic ring, or alkyl of 1-5 carbon atoms which is substituted by one or more of halogen atoms, hydroxy, carboxy, alkoxy, alkoxycarbonyl or an amino group; or amino.

10

6. The method of claim 5, wherein said Type IV phosphodiesterase inhibitor is rolipram.


7. The method of claim 5, wherein said agonist of an A_{2A} adenosine receptor is

15



and said Type IV phosphodiesterase inhibitor is rolipram.

8. The method of claim 1, wherein said agonist of an A_{2A} adenosine receptor is



9. The method of claim 2, wherein said A_{2A} adenosine receptor agonist and said Type IV phosphodiesterase inhibitor are coadministered together to the patient in need thereof.
10. A pharmaceutical composition comprising an effective amount of an agonist of an A_{2A} adenosine receptor in combination with an effective amount of a Type IV phosphodiesterase inhibitor.

1/9




Figure 1

2/9




Figure 2

3/9




Figure 3

4/9




Figure 4

⇓
P<.05 COMPARED TO TNF + ADA

5/9

NO ROLIPRAM




Figure 5A

*ROLIPRAM (100nM)




Figure 5B

6/9




Figure 6

7/9




Figure 7A




Figure 7B




Figure 8




Figure 9

9/9




Figure 10




Figure 11

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 00/14548

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/00 A61K31/7076 A61P29/00 //(A61K31/7076, 31:4015)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 877 180 A (LINDEN JOEL M ET AL) 2 March 1999 (1999-03-02) see the whole document, especially column 7 lines 36-column 8; column 9 line 13; column 11 lines 36-39; column 13 lines 5-28; column 14 lines 34-37 ---	1-10
X	SULLIVAN ET AL.: "Role of A2a adenosine receptors in inflammation" DRUG DEVELOPMENT RESEARCH, vol. 45, no. 3-4, 1998, pages 103-112, XP000978332 see the whole document, especially page 106 right column and page 109 left column last paragraph --- -/-	1-10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

S document member of the same patent family

Date of the actual completion of the international search

24 January 2001

Date of mailing of the international search report

01/02/2001

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Gac, G

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/14548

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
X	BUSTER B(A) ET AL: "The effect of adenosine receptor agonists on neutrophil pleocytosis and blood-brain barrier pathophysiology in experimental bacterial meningitis" ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, XX, XX, vol. 37, 1997, page 39 XP002104913 see abstract B-72 ---	1-6,8-10
X	WO 98 57651 A (MCAFEY DONALD A ;DISCOVERY THERAPEUTICS INC (US); MARTIN PAULINE L) 23 December 1998 (1998-12-23) abstract page 2 see page 3 especially lines 17-18 page 8, line 23 - line 29 see page 9 lines 1-18, especially lines 2,3,8-10 page 11, line 3 - line 23 page 12, line 2 - line 3 claims 10,11	1,3,4,7,8
Y	---	2,5,9,10
Y	SULLIVAN GW ET AL: "The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-alpha-primed neutrophil oxidative activity" INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, US, ELMSFORD, NY, vol. 17, no. 10, 1995, pages 793-803, XP002104914 ISSN: 0192-0561 the whole document ---	2,5,9,10
P,X	WO 99 34804 A (UNIV VIRGINIA) 15 July 1999 (1999-07-15) the whole document ---	1-10
P,X	SULLIVAN ET AL.: "Neutrophil A2a adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with type IV phosphodiesterase inhibitor, Rolipram" JOURNAL OF INFECTIOUS DISEASES, vol. 180, no. 5, November 1999 (1999-11), pages 1550-1560, XP000978330 the whole document -----	1-6,8-10

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 3 and 5 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed (only for rolipram and compounds of claim 4). In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Moreover, present claims 1,2,9,10 relate to compounds and methods defined by reference to a desirable property, namely being and "agonist of an A2a adenosine receptotr" or a "type IV phosphodiesterase inhibitor". The claims cover all compounds/methods property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds (or methods). In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound or a method by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds (or methods) of claims 4 and/or 6.

Therefore the search has been carried out :

- incompleately on claims 1-3, 5-10
- completely on claim 4 .

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/14548

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5877180 A	02-03-1999	NONE	
WO 9857651 A	23-12-1998	AU 8074098 A EP 1014995 A	04-01-1999 05-07-2000
WO 9934804 A	15-07-1999	AU 2108299 A EP 1044004 A	26-07-1999 18-10-2000